A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

NCT01460719 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: V212

Sponsor

Merck Sharp & Dohme LLC